Kura Oncology Inc (KURA : NASDAQ)
Common Stock
$11.20
USD
+0.00 (%)
Last updated: 2026-09-17
Get KURA alerts:
KURA
Kura Oncology Inc
Performance
1 Day
-0.88%
1 Week
-7.36%
1 Month
-0.71%
YTD
+17.03%
Key Statistics
Market Cap
$996.36M
52W High
$13.90
52W Low
$7.36
P/E Ratio
-
50 Day MA
$11.18
200 Day MA
$9.82
Beta
0.43
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $11.39 | $12.20 | $11.35 | $11.72 | $11.72 | 1,852,046 |
| 9/16/2026 | $11.31 | $11.52 | $11.14 | $11.20 | $11.20 | 1,793,131 |
| 9/15/2026 | $11.48 | $11.48 | $11.03 | $11.30 | $11.30 | 1,827,385 |
| 9/14/2026 | $11.37 | $11.68 | $11.25 | $11.56 | $11.56 | 1,457,824 |
| 9/11/2026 | $11.58 | $11.75 | $11.34 | $11.39 | $11.39 | 2,117,528 |
| 9/10/2026 | $12.00 | $12.00 | $11.44 | $11.57 | $11.57 | 1,814,433 |
| 9/9/2026 | $12.50 | $12.61 | $11.99 | $12.09 | $12.09 | 2,213,106 |
| 9/8/2026 | $12.93 | $12.93 | $12.50 | $12.52 | $12.52 | 1,511,765 |
| 9/4/2026 | $12.94 | $13.27 | $12.89 | $13.25 | $13.25 | 1,313,519 |
| 9/3/2026 | $13.25 | $13.29 | $12.85 | $13.15 | $13.15 | 1,477,983 |
Analyst Price Targets
Based on 15 analysts covering KURA · as of Sep 17, 2026
Wall Street analysts forecast KURA stock price to rise 185.7% over the next 12 months.
Consensus
Strong Buy4.53 / 5.00
Avg. Target
US$32.00
+185.7% Upside
Current Price
US$11.20
Last close
Analyst Breakdown (15 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on KURA's historical volatility
30-Day Vol
61.6%
Annualized
90-Day Vol
58.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$14.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$12.44 | US$10.06 – US$15.38 |
| 60 trading days | US$13.20 | US$9.77 – US$17.83 |
| 90 trading days | US$14.01 | US$9.70 – US$20.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $77.22M
- EBITDA
- $-316.80M
- Profit Margin
- 0.00%
- ROE (TTM)
- -167.71%
- EPS (Diluted)
- -3.37
- Book Value
- 0.54
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About KURA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |